Tempus AI, Inc. (NASDAQ:TEM) Given Consensus Recommendation of “Hold” by Analysts

Tempus AI, Inc. (NASDAQ:TEM) has been assigned an average recommendation of “Hold” from the seventeen brokerages that are currently covering the stock, Marketbeat reports. Two investment analysts have rated the stock with a sell recommendation, six have issued a hold recommendation and nine have assigned a buy recommendation to the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $65.6923.

TEM has been the topic of several recent research reports. Weiss Ratings cut shares of Tempus AI from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday. Wolfe Research assumed coverage on shares of Tempus AI in a research note on Tuesday, June 2nd. They set a “peer perform” rating for the company. BTIG Research increased their target price on shares of Tempus AI from $70.00 to $80.00 and gave the company a “buy” rating in a research note on Thursday, August 20th. Guggenheim raised their target price on shares of Tempus AI from $60.00 to $65.00 and gave the stock a “buy” rating in a report on Thursday, July 16th. Finally, TD Cowen restated a “buy” rating on shares of Tempus AI in a research report on Wednesday, July 15th.

Insider Buying and Selling at Tempus AI

In other news, CFO James William Rogers sold 26,313 shares of the business’s stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $60.00, for a total transaction of $1,578,780.00. Following the sale, the chief financial officer directly owned 106,024 shares of the company’s stock, valued at $6,361,440. The trade was a 19.88% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Ryan Fukushima sold 14,286 shares of the company’s stock in a transaction on Friday, August 21st. The shares were sold at an average price of $70.00, for a total value of $1,000,020.00. Following the sale, the chief executive officer directly owned 47,420 shares of the company’s stock, valued at approximately $3,319,400. This represents a 23.15% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 1,041,238 shares of company stock worth $56,768,767. 24.26% of the stock is owned by insiders.

Institutional Investors Weigh In On Tempus AI

Hedge funds have recently made changes to their positions in the company. JPL Wealth Management LLC purchased a new stake in Tempus AI in the 3rd quarter worth about $26,000. Los Angeles Capital Management LLC purchased a new position in Tempus AI during the 4th quarter valued at about $27,000. Harvest Fund Management Co. Ltd purchased a new position in Tempus AI during the 3rd quarter valued at about $38,000. EMC Capital Management purchased a new stake in shares of Tempus AI in the second quarter worth approximately $29,000. Finally, Danske Bank A S purchased a new stake in shares of Tempus AI in the third quarter worth approximately $48,000. Hedge funds and other institutional investors own 24.22% of the company’s stock.

Tempus AI Trading Down 9.4%

Shares of TEM stock opened at $64.04 on Friday. The stock has a 50-day simple moving average of $54.63 and a 200 day simple moving average of $51.80. Tempus AI has a fifty-two week low of $40.77 and a fifty-two week high of $104.32. The stock has a market capitalization of $11.55 billion, a P/E ratio of -44.47 and a beta of 3.58. The company has a quick ratio of 3.16, a current ratio of 3.30 and a debt-to-equity ratio of 3.06.

Tempus AI (NASDAQ:TEM) last issued its quarterly earnings results on Thursday, July 30th. The company reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.14) by $0.10. Tempus AI had a negative net margin of 17.77% and a negative return on equity of 50.28%. The firm had revenue of $382.49 million for the quarter, compared to analysts’ expectations of $379.69 million. During the same period in the previous year, the business earned ($0.22) earnings per share. Tempus AI’s revenue for the quarter was up 21.6% compared to the same quarter last year. On average, sell-side analysts expect that Tempus AI will post -1.38 earnings per share for the current fiscal year.

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.